VITILIGO STUDY
Take part in a new Vitiligo research study for a potential new treatment.
This study aims to evaluate the safety and effectiveness of an investigational treatment for vitiligo. By participating, you could help advance vitiligo research and contribute to the development of potential new treatment options.
Critical Eligibility Criteria:
To take part in this study, you will need to meet all the following:
- Aged between 18 and 65 years
- Diagnosed with vitiligo
- Willing to attend study visits and comply with study requirements
Unfortunately, if you have another active inflammatory skin disease or have received certain vitiligo treatments recently, this study may not be the right fit for you. Additional criteria apply.
Commitment:
Your participation will involve attending scheduled study visits at a clinical trial site, receiving study-related care, and completing follow-up assessments.
Locations:
New Zealand and Australia (NSW | QLD)
If you take part in this research study, there will be:
Reimbursement of costs
For out-of-pocket expenses, such as travel and parking.
Convenience
There are no overnight stays
Free study-related medical care
Be among the first to access potential new research treatments before they are widely available.
Expert medical monitoring
Receive top-tier medical care and monitoring from experienced healthcare professionals.
Contribution to medical research
Help investigate a potential new treatment that could improve the lives of individuals with vitiligo
Register your interest now
or scroll down to read the study FAQs
Study Guide
01
Who can take part in this study?
-
To take part, you must meet the following criteria (additional criteria apply):
- Aged between 18-65 years
- Diagnosed with non-segmental vitiligo
- Willing to attend study visits and follow study procedures
02
Who is unable to take part in this study?
+
Unfortunately, you will not be able to participate if:
- You have another active inflammatory skin disease
- You have received certain vitiligo treatments recently
- You have a medical condition that might interfere with study participation
Additional exclusion criteria apply.
03
What does the study involve for participants?
+
If eligible, your participation is expected to last approximately 30 weeks, and you will need to attend scheduled study visits at a clinical site. This includes:
- Screening visit – to confirm eligibility
- 11 additional visits spread over the next 26 weeks for treatment and follow up.
Participation is voluntary, and you can withdraw from the study at any time.
04
What is the purpose of this study?
+
This study aims to assess the safety and effectiveness of an investigational treatment for vitiligo, which may help restore pigmentation and improve skin appearance.
05
What is Vitiligo?
+
Vitiligo is a skin condition that causes loss of pigmentation, resulting in white patches on the skin. It occurs when the immune system attacks pigment-producing cells called melanocytes. The condition can affect self-esteem and quality of life, making effective treatments important.
06
Why is this study important?
+
Vitiligo affects millions worldwide, and current treatment options are limited. This study explores a potential new therapeutic approach that may offer improved outcomes for people with vitiligo.
07
Who is sponsoring this study?
+
This study is being sponsored by Forte Biosciences Australia Pty Ltd
08
Where is my nearest study site?
+
Here is a list of all of the sites who are currently recruiting for this study:
09
What if I have other questions about the study?
+
We are here for you! Head to our Evrima Help Centre and search for answers relating to clinical trials, study information and managing your Evrilink account
This study has been approved by an independent Human Research Ethics Committee
Help make medical research breakthroughs happen.
Need help with clinical trial information?
Search our Evrima help Centre for answers related to information about our active studies, information about managing your Evrilink account, and general clinical trial knowledge!
Read our FAQs